Cegardex®
Human papillomavirus (HPV) vaccine [types 6, 11, 16, 18], quadrivalent (recombinant, adsorbed).1
Indications
Prevention of:
- precancerous genital lesions (cervical intraepithelial neoplasia grades 1/2/3 (CIN), adenocarcinoma in situ of the cervix (AIS), vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN) grades 1/2/3, precancerous lesions of the anal canal (anal intraepithelial neoplasia (AIN) grades 1/2/3)) caused by human papillomavirus (HPV) types 6, 11, 16 and 18;
- cancers of the cervix, vulva, vagina and anal canal caused by HPV types 16 and 18;
- anogenital warts (condylomas) caused by HPV types 6 and 11.1
Age of Use
For persons of both sexes aged 9 to 45 years.1
Scientific Publications
- Belaya Yu.M., Zarochentseva N.V., Lopukhov P.D. HPV infection vaccine prevention: regional experience of the Moscow Region. Issues of Practical Colposcopy. Genital Infections. 2025; 2: 6–9. DOI: 10.46393/2782_6392_2025_2_6–9.
- Belotserkovtseva L.D., Mayer Yu.I., Konareva I.G. Results of cervical screening in women vaccinated in adolescence against human papillomavirus within the regional HPV vaccination program in Khanty-Mansi Autonomous Okrug–Yugra. Reproductive Health of Children and Adolescents. 2025. Vol. 21, No. 3. pp. 5–16. DOI: https://doi.org/10.33029/1816-2134-2025-21-3-5-16.
- Gomberg M.A., Kim D.G. Anogenital warts: from challenges of epidemiological accounting to confirmed impact of vaccine prevention on population health as a marker of global success in combating HPV. Clinical Dermatology and Venereology. 2025; 24(4): 504–510. https://doi.org/10.17116/klinderma202524041504.
- Krysanov I.S., Kokushkin K.A. Modeling the cost-effectiveness of vaccinating adolescents of both sexes against HPV. Journal of Infectology. 2025; 17(4): 132–146. DOI: 10.22625/2072-6732-2025-17-4-132-146.
- Feldblyum I.V., Subbotina K.A., Golodnova S.O., et al. Immunological efficacy and safety of the recombinant quadrivalent (types 6, 11, 16, 18) HPV vaccine Cegardex® in adult immunization (results of clinical trials in the Russian Federation). Issues of Practical Colposcopy. Genital Infections. 2025; 3: 6–15. DOI: 10.46393/27826392_2025_3_6–15.
Vaccination Schedule
The recommended vaccination course consists of 3 doses administered according to the schedule (0–2–6 months) for adults:
- first dose — on the chosen day;
- second dose — 2 months after the first;
- third dose — 6 months after the first.1
Children aged 14 to 17 years (inclusive):1
The dosing regimen does not differ from that for adults.
Children aged 9 to 13 years (inclusive):1
- A 2-dose vaccination schedule with Cegardex may be used (0–6 months).
- Alternatively, Cegardex may be administered according to the 3-dose schedule as described for adults.
Manufacturing and Registration
- Marketing authorization holder — LLC “Nanolek”.2
- Registered in the Russian Federation in 2025.2
- Manufactured at the Nanolek Biomedical Manufacturing Complex (BMC).2
Official Documents
-
1.
Summary of Product Characteristics for Cegardex®.
Access date: 23 January 2026.
-
2.
State Register of Medicinal Products.
Access date: 23 January 2026.